Peer Reviewed

1

Document Type

Article

Publication Date

1-2-2008

Keywords

Cystic Fibrosis, Enzyme Inhibitors, Humans, Leukocyte Elastase

Comments

The Version of Scholarly Record of this Article is published Expert Opinion on Therapeutic Targets 2008, available online at: http://www.tandfonline.com/ DOI: 10.1517/14728222.12.2.145

Abstract

BACKGROUND: Cystic fibrosis (CF) is a lethal hereditary disease characterised by neutrophil-dominated lung inflammation. These abundant neutrophils produce neutrophil elastase (NE), a destructive serine protease that has direct actions on extracellular matrix proteins and has a role in the host response to inflammation and infection.

OBJECTIVE: This review examines the prospect of developing novel therapies for CF by targeting NE. The authors explore the functions of NE and of naturally-occurring and synthetic NE inhibitors.

METHODS: A literature search was conducted exploring the functions of NE and inhibitors of NE; naturally occurring and synthetic.

CONCLUSIONS: Targeting NE in CF offers therapeutic potential, but optimal inhibitors that can be delivered safely and effectively to the lung are still under development.

Disciplines

Medicine and Health Sciences

Citation

Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert Opinion on Therapeutic Targets. 2008;12(2):145-57.

PubMed ID

18208364

DOI Link

10.1517/14728222.12.2.145

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Share

COinS